logo
Twitter
Discord
Email
logo
Quipt Home Medical Corp.

Quipt Home Medical Corp.

NASDAQ•QIPT
CEO: Mr. Gregory J. Crawford
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-10
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Contact Information
1019 Town Drive, Wilder, KY, 41076, United States
859-878-2220
quipthomemedical.com
Market Cap
$109.70M
P/E (TTM)
-10.7
33
Dividend Yield
--
52W High
$3.27
52W Low
$1.35
52W Range
61%
Rank54Top 66.0%
3.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$58.29M-8.88%
4-Quarter Trend

EPS

-$0.07+76.75%
4-Quarter Trend

FCF

$4.43M-54.10%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Months Revenue Decline Nine months revenue totaled $177.05M USD, down 4.1% due to external industry challenges impacting collections.
Operating Cash Flow Increase Operating cash flow provided $27.91M USD for nine months, showing a $2.51M USD increase year-over-year.
Stock Comp Expense Rises Stock-based compensation expense for nine months increased to $2.63M USD due to recent long-term incentives granted.
Post-Period Acquisition Closed Acquired Mediserve on July 1, 2025, for $2.60M USD cash/holdback, expanding footprint in Tennessee/Virginia.

Risk Factors

Net Loss Significantly Worsens Net loss for nine months reached $7.15M USD, worsening by $3.33M USD compared to prior year period.
Adjusted EBITDA Decreases Adjusted EBITDA declined $3.41M USD for nine months, settling at $41.02M USD due to operational pressures.
Regulatory and Activist Pressures DOJ CID investigation and activist shareholder actions introduce uncertainty and increase professional fees expense by $0.88M USD (9M).
Variable Rate Debt Exposure Variable rate debt exposes $7.01M USD principal to interest rate risk; 1% rise costs $70K annually in interest expense.

Outlook

Driving Organic Growth Focus Priorities include driving organic revenue growth, achieving operational net profit, and expanding Adjusted EBITDA moving forward.
Operational Efficiency Optimization Focus remains on optimizing structure, enhancing efficiencies, reducing redundancies, and centralizing processes for sustainable long-term growth.
Sufficient Liquidity Expected Current liquidity sources, including $14.30M USD credit availability, sufficient to fund operations for next twelve months.
Evaluating New Tax Legislation Evaluating impact of recently enacted OBBBA legislation regarding interest deductibility and capital expenditure expensing rules.

Peer Comparison

Revenue (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
Quipt Home Medical Corp.QIPT
$229.68M
-8.2%
Xtant Medical Holdings, Inc.XTNT
$133.08M
+16.9%

Gross Margin (Latest Quarter)

Quipt Home Medical Corp.QIPT
97.5%
+23.6pp
MacroGenics, Inc.MGNX
81.6%
-16.7pp
Xtant Medical Holdings, Inc.XTNT
68.6%
+6.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRE$190.55M-4.3-28.9%1.1%
APYX$154.18M-10.6-153.8%8.0%
ANIK$139.02M-4.2-22.1%12.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Dec 15, 2025
|
EPS:$0.03
|
Revenue:$87.46M
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $58.29M-8.9%
    |
    EPS: $-0.07+76.8%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $57.38M-6.3%
    |
    EPS: $-0.07+303.4%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Dec 31, 2024|Filed: Feb 10, 2025|
    Revenue: $61.38M-1.9%
    |
    EPS: $-0.03-30.6%
    Beat

  • Form 10-K - FY 2024

    Period End: Sep 30, 2024|Filed: Dec 16, 2024|
    Revenue: $245.92M+16.2%
    |
    EPS: $-0.16-128.6%
    Miss

  • Form 40-F/A - FY 2023

    Period End: Sep 30, 2023|Filed: Apr 2, 2024|
    Revenue: $211.68M+51.3%
    |
    EPS: $-0.07-150.0%
    Miss

  • Form 40-F - FY 2023

    Period End: Sep 30, 2023|Filed: Dec 22, 2023|Refer to amended data

  • Form 40-F - FY 2022

    Period End: Sep 30, 2022|Filed: Dec 23, 2022|
    Revenue: $139.86M+36.6%
    |
    EPS: $0.14+170.0%
    Beat

  • Form 40-F - FY 2021

    Period End: Sep 30, 2021|Filed: Jan 27, 2022|
    Revenue: $102.35M+39.9%
    |
    EPS: $-0.20-17.6%
    Beat